Traws Pharma
TRAW
28 hedge funds and large institutions have $1.54M invested in Traws Pharma in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 4 closing their positions.
0.01% less ownership
Funds ownership: 0.34% → 0.33% (-0.01%)
7% less funds holding
Funds holding: 30 → 28 (-2)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
35% less capital invested
Capital invested by funds: $2.36M → $1.54M (-$821K)
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$134K |
| 2 |
VF
Virtu Financial
New York
|
+$28.4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$28K |
| 4 |
EDRH
Edmond de Rothschild Holding
Chambesy,
Switzerland
|
+$8.07K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$30 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$155K |
| 2 |
Two Sigma Advisers
New York
|
-$63.8K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$20.3K |
| 4 |
Jane Street
New York
|
-$20K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$18K |
TRAW Hedge Fund Activity: Q3 2022 in Review
28 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q3 2022, worth a combined $1.54M — down 35% from $2.36M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of TRAW and 3 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 3 added.
The largest buyer was Vanguard Group, adding an estimated $134K. The largest seller was Renaissance Technologies, cutting an estimated $155K.
- 28 institutional investors held Traws Pharma (TRAW) as of Q3 2022, down from 30 in Q2 2022.
- Funds reported $1.54M of Traws Pharma stock for Q3 2022, down 35% quarter-over-quarter.
- 3 funds opened new Traws Pharma positions in Q3 2022 and 4 closed out, a net change of -1 holder.
- The largest Traws Pharma buyer in Q3 2022 was Vanguard Group, an estimated $134K added.
- The largest Traws Pharma seller in Q3 2022 was Renaissance Technologies, an estimated $155K sold.
Based on aggregated 13F filings for Q3 2022.